![](https://investorshub.advfn.com/uicon/275298.png?cb=1541149751)
Friday, February 19, 2021 1:34:57 PM
Are we about to see an announcement of PUR1800 (or even the resurfacing of PUR5700) being studied/used as therapeutic for COVID-19? A JnJ / Pulmatrix collaboration to be announced in addition to their target indication of COPD & Lung Cancer?
Lots of literature out there on P38 MAPK Kinase Inhibitors being repurposed for Covid-19 therapeutic treatment.
Example Article 1:
"The authors conclude that “safe and well tolerated p38 MAPK inhibitors that are already in clinical development could be readily repurposed in randomized, controlled trials enrolling patients at risk for serious COVID-19 complications.”
https://sparkmed.stanford.edu/dr-grimes-authors-paper-on-p38-mapk-pathway-in-covid-19/
Example Article 2:
"A number of p38 inhibitors are in the clinical stage and should be considered for clinical trials in serious COVID-19 infection."
https://pubmed.ncbi.nlm.nih.gov/32422320/
PUR1800 Fact Sheet:
![](http://charts.stocktwits.com/production/original_292180299.png)
All comments are solely my opinion. Please formulate your own opinion and act on your own accord on all actions you take.
Recent PULM News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/31/2024 04:15:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:45:16 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:00:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 01:20:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 01:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:06:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:00:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 02:20:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:05:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 01:20:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 01:05:29 PM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM